ThomasJGeorgeJr.MDFACP

Oncology • Gainesville, FL

Gastrointestinal Cancer, Clinical Pharmacology, Clinical Informatics

Professor, Medicine, University of Florida College of Medicine

Join to view full profile

Dr. George is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. George's full profile

Already have an account?

Office
1600 PO Box
Gainesville, FL 32610
Phone+1 352-265-0101

Education & Training

University of FloridaFellowship, Hematology and Medical Oncology, 2002 - 2005
University of FloridaResidency, Internal Medicine, 1998 - 2002
University of Florida College of MedicineClass of 1998

Certifications & Licensure

FL State Medical License 1999 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma Start of enrollment: 2011 Oct 01
Completed
Phase 2
Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer Start of enrollment: 2011 Nov 01
Completed
Phase 2
Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma Start of enrollment: 2012 Jul 01
Completed
Phase 2
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Start of enrollment: 2013 May 01
Terminated
Phase 3
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
Completed
Phase 2
Acupuncture for Unintentional Weight Loss and Anorexia With GI Cancer Start of enrollment: 2014 Oct 01
Completed
Not Applicable
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Start of enrollment: 2016 May 19
Active, not recruiting
Phase 2
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer Start of enrollment: 2017 Jan 11
Completed
Phase 2
Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer Start of enrollment: 2018 May 14
Completed
Phase 2
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Start of enrollment: 2018 Aug 13
Completed
Phase 2
A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer Start of enrollment: 2020 Jan 31
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis.
Benoist Chibaudel, Morteza Raeisi, Romain Cohen, Greg Yothers, Richard M Goldberg
Journal of Clinical Oncology. 2024-12-10
North American Cancer Center Clinical Research Capacity and Benchmarking in the Postpandemic Era.
Margaret Kasner, Angela H Fritsche, Man Chong Leong, Kendra Cameron, Carrie B Lee
JCO Oncology Practice. 2024-12-01
4 citations
SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.
Sandip P Patel, Elizabeth Guadarrama, Young Kwang Chae, Michael J Dennis, Benjamin C Powers
Cancer. 2024-09-01

Journal Articles

Using Photography to Explore Psychological Distress in Patients with Pancreatic Cancer and Their Caregivers: A Qualitative Study
Thomas George Jr., MD, Supportive care in cancer

Lectures

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)â€”First experimental arm (EA) initial resu...
2019 ASCO Annual Meeting - 6/1/2019
Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer: NSABP FR-2.
2019 ASCO Annual Meeting - 6/1/2019
Final results from a phase II study of 5-fluorouracil, oxaliplatin, and dasatinib (FOLFOX-D) in previously untreated metastatic pancreatic adenocarcinoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemotherapy (NAC) in stage II-IV rectal cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Join now to see all

Press Mentions

NRG Trial Suggests Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer Is SafeJune 1st, 2019
How Social Media Can Advance Cancer ResearchFebruary 15th, 2019
UM, UF Research Team Gets $3.2M Grant To Study Cannabis in Breast Cancer TreatmentsNovember 15th, 2023
Join now to see all